Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers ...

Molecular-cloning studies have revealed the existence of five molecularly distinct mammalian muscarinic acetylcholine receptors (mAChRs), M 1 –M 5, which are all members of the superfamily of class I ...

The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally ...

Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side-effect ...

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. ("Neurocrine”) ...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with ...

Key roles in modulating cognition and behavior made the M1 muscarinic acetylcholine receptor (mAChR) a prime target for Alzheimer disease drug developers dating back nearly two decades. However, ...

In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...

Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does ...